UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study

JNCI : Journal of the National Cancer Institute, 2008-04, Vol.100 (8), p.552-562

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

British journal of cancer, 2012-09, Vol.107 (6), p.956-960

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer

European journal of cancer supplements, 2008-09, Vol.6 (10), p.3-11

2008

Link zum Volltext

Verfügbarkeit prüfen

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results

Acta radiologica (1987), 2012-07, Vol.53 (6), p.628-636

2012

Link zum Volltext

Verfügbarkeit prüfen

Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics

British Journal of Cancer, 1999-12, Vol.81 (7), p.1165-1173

1999

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial

JNCI : Journal of the National Cancer Institute, 2008-01, Vol.100 (2), p.121-133

2008

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

Annals of oncology, 2005-08, Vol.16 (8), p.1297-1304

2005

Link zum Volltext

Verfügbarkeit prüfen

Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

Cancer, 2010-09, Vol.116 (18), p.4227-4237

2010

Link zum Volltext

Verfügbarkeit prüfen

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

Annals of oncology, 2007-09, Vol.18 (9), p.1484-1492

2007

Link zum Volltext

Verfügbarkeit prüfen

Ready for a comeback of natural products in oncology

Biochemical pharmacology, 2009-05, Vol.77 (9), p.1447-1457

Bailly, Christian

2009

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

British journal of cancer, 2003-05, Vol.88 (9), p.1339-1345

2003

Link zum Volltext

Verfügbarkeit prüfen

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

British journal of cancer, 2012-08, Vol.107 (5), p.800-807

2012

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro

Journal of cancer research and clinical oncology, 2009-02, Vol.135 (2), p.227-234

2009

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

Breast cancer research and treatment, 2012-08, Vol.134 (3), p.903-913

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

British journal of cancer, 2014-04, Vol.110 (9), p.2170-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02

Oncology, 2012-01, Vol.82 (3), p.131-138

2012

Link zum Volltext

Verfügbarkeit prüfen

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

Oncology, 2010-01, Vol.79 (3-4), p.197-203

2010

Link zum Volltext

Verfügbarkeit prüfen

Proteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors

The American journal of pathology, 2002-02, Vol.160 (2), p.441-447

2002

Link zum Volltext

Verfügbarkeit prüfen

Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis

Oncogene, 1999-06, Vol.18 (24), p.3574-3582

1999

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

European journal of clinical pharmacology, 2014-02, Vol.70 (2), p.155-166

2014

Link zum Volltext

Verfügbarkeit prüfen

Recent Developments in Treatment Stratification for Metastatic Breast Cancer

Drugs (New York, N.Y.), 2011-11, Vol.71 (16), p.2099-2113

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

Annals of oncology, 2008-07, Vol.19 (7), p.1255-1260

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

British journal of cancer, 2008-03, Vol.98 (5), p.894-899

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer

Breast cancer research and treatment, 2005-09, Vol.93 (1), p.67-74

2005

Link zum Volltext

Verfügbarkeit prüfen

Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2

Breast cancer research and treatment, 2011-10, Vol.129 (3), p.777-784

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 111

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(111)

Sprache

Englisch
(111)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results

Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

Ready for a comeback of natural products in oncology

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

Proteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors

Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis

Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

Recent Developments in Treatment Stratification for Metastatic Breast Cancer

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer

Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2

Aktive Filter

Suchergebnisse filtern